Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06840756

Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes

Red blood cell (RBC) transfusions are selected based upon matching donor and recipient blood group: donor and recipient sex are not considered when selecting blood for transfusion. Hence, transfused patients can currently receive sex-matched and/or unmatched RBCs when transfusions are given. Sex-matched stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. Recent exploratory studies have also suggested that patient outcomes could be improved by sex-matching for RBC transfusion. There is emerging evidence of underlying biologic mechanism(s) to support these observations. This study is designed as a randomized controlled trial and will explore the impact on patients who receive RBC transfusions from donors of the same sex ("sex-matched") compared with donors of the opposite sex ("sex-mismatched").

The trial will study adult patients admitted to the Intensive Care Unit who require an RBC transfusion. Patients will be assigned (through a process called randomization) to receive sex-matched RBCs or sex-mismatched RBCs to determine if there is a difference in mortality between those receiving matched versus mismatched RBCs. The results of this trial could have direct implications on resources, blood inventory, and RBC transfusion ordering practices.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hamilton General Hospital, Hamilton, Ontario, Canada

Loading trial locations.

About this study

Background: Red blood cell (RBC) transfusions are selected based upon donor and recipient blood group compatibility without consideration of donor and recipient sex. Stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. The Principal Investigator has completed a systematic review/meta-analysis and a 40,000 patient exploratory analysis; both showed a signal of benefit from sex-matched RBC transfusion. Biological findings to support the hypothesis that sex-matched RBC transfusions improve survival in recipients are also emerging.

Controversial results have emerged from observational studies and a randomized controlled trial (RCT) regarding recipient mortality from sex-mismatched RBC transfusions; hence, equipoise exists.

The Principal Investigator completed a multisite pilot RCT that showed feasibility for conducting a large-scale RCT and has helped to inform design for this study proposal. The goal of this research project is to develop a precision transfusion strategy based on sex-matching of blood donor and recipient to minimize adverse effects and improve patient outcomes post-transfusion.

Overall Research Question: In transfused adult patients admitted to the Intensive Care Unit (ICU), do donor-recipient sex-matched RBC transfusions result in improved mortality compared to sex-mismatched RBC transfusions?

Methods: This study is a superiority RCT with pragmatic features that will occur across participating sites in Canada.

Study population: adult patients (age≥18) who are hospitalized with admission to an eligible ICU and requiring RBC transfusion.

Intervention: donor-recipient sex-matched RBC transfusions. Comparison: donor-recipient sex-mismatched RBC transfusions.

Primary Outcome: 30 day mortality from time of randomization. Secondary Outcomes: time to death, 30 day in-hospital mortality, 90 day mortality, hemoglobin and creatinine increment, ICU and hospital lengths of stay, number/type of transfused products and cost effectiveness analysis. Subgroup analyses will consider recipient sex, age, transfusion exposure, blood type, admitting diagnosis, baseline hemoglobin/creatinine.

Expertise: The study team is uniquely positioned with extensive knowledge and expertise in transfusion medicine, research methodology, conduct of large pragmatic trials, and biostatistics. The study team will collaborate with Canadian Blood Services and experts in blood utilization, and operational modeling. This study is supported and endorsed by the Canadian Transfusion Trials Group.

Importance & Outcomes: Anemia is common in critically ill patients; as many as 90% of patients will become anemic by the third day of their ICU admission. Between 20% and 40% of critically ill patients admitted to the ICU will require RBC transfusion; each patient will receive on average 2 to 5 RBC units. The Age of Blood Evaluation (ABLE) study showed a 90 day all cause mortality rate of 35-37% in the transfused ICU population studied. The pilot study reflected similar mortality rates. If providing sex-matched transfusions can decrease mortality, this could translate to high numbers of preventable deaths given that 85 million RBC units are transfused globally each year. If this study finds that donor-recipient sex-matching saves lives, this would require changes at the level of the blood supplier to identify sex on each RBC unit, and changes at the hospital level that would incorporate sex-matching into the selection of compatible blood for each patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (age ≥18);
  • Admission to a participating ICU;
  • Requiring RBC transfusion.

Exclusion criteria

  • Requirement for a specialized RBC product or unit not readily available in inventory (e.g., rare blood type, washed RBCs, complex RBC antibodies, etc.);
  • Massively bleeding patient (i.e., ≥4 units of blood ordered at one time, or Massive Hemorrhage Protocol initiated, or an urgent blood request made);
  • Sex unknown or sex other than male or female (i.e. intersex);
  • Do not have a valid Ontario Health Insurance Plan (OHIP) health card number.

Treatment and study plan

Sex-mismatched red blood cell transfusions

Biological

Sex-mismatched red blood cell transfusions

Sex-matched red blood cell transfusions

Biological

Sex-matched red blood cell transfusions

Primary outcomes

  1. 30 day mortality

    Time frame: From randomization to 30 days post-randomization.

    Death within 30 days of randomization.

Secondary outcomes

  1. 30 day in-hospital mortality

    Time frame: From randomization to 30 days post-randomization.

    In-hospital death within 30 days of randomization.

  2. 90 day mortality

    Time frame: From randomization to 90 days post-randomization.

    Death within 90 days of randomization.

  3. Time to 30 day in-hospital mortality

    Time frame: From randomization to 30 days post-randomization.

    Time to in-hospital death within 30 days of randomization.

  4. Hemoglobin increment

    Time frame: From time of randomization until death or discharge from ICU; up to 90 days post randomization.

    Lowest hemoglobin post-randomization during ICU admission.

  5. Need for renal replacement therapy

    Time frame: From time of randomization during ICU admission, until death or discharge from ICU; up to 90 days post randomization.

    Need for renal replacement therapy e.g. CRRT or HD post randomization during ICU admission.

  6. ICU/hospital length of stay

    Time frame: From randomization to 30 days post-randomization.

    The number of ICU-free days over 30 days and the number of days in hospital over 30 days.

  7. Number/type/volume/dose of transfused product

    Time frame: From randomization to 90 days post-randomization.

    Total number of transfusion interventions, cumulative proportion of units received that were from a sex-mismatched donor

  8. Transfusion reactions

    Time frame: From randomization to 30 days post-randomization.

    Reactions related to RBC transfusions.

  9. Cost effectiveness

    Time frame: From randomization to 90 days post-randomization.

    Cost effectiveness measured using the incremental cost per life year saved (ICER) between sex-matched and mismatched transfusions.

Study contacts

Contact information is provided by the study sponsor or research team.

Bambie Levoy-Jones, Honours Bachelor of Science

CONTACT

[email protected]

1-905-525-9140 ext. 24928

Michelle Zeller, Doctor of Medicine

CONTACT

[email protected]

1-905-525-9140 ext. 73928

Sponsors and collaborators

Lead sponsor

Michelle Zeller

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)

Registry information

Official study title

Effects of Donor-recipient Sex-matched Versus Sex-mismatched Red Blood Cell Transfusion on Outcomes in Critically Ill Adult Patients

Acronym: SexMATTERS RCT

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Feb 21, 2025
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.